Paxlovid can prevent #LongCovid
The latest from our team in @JAMAInternalMed
by @Biostayan @TaeyoungChoi93 @zalaly
A thread
jamanetwork.com/journals/jamai…
In this study of 281,793 people with SARS-CoV-2 infection who are eligible for Paxlovid
35,717 received Paxlovid
246,076 received no antiviral treatment
We show that people who got treated with Paxlovid had 26% reduced risk of developing Long Covid
jamanetwork.com/journals/jamai…
Paxlovid reduced risk of 10 of 13 components of Long Covid including
Dysrhythmia
Ischemic heart disease
Pulmonary embolism
Deep vein thrombosis
Fatigue & mailaise
Acute kidney disease
Muscle pain
Neurocognitive impairment
Dysautonomia
Shortness of breath
ja.ma/ziyad
Paxlovid use was also associated with
47% reduced risk of post-acute death
and
24% reduced risk of post-acute hospitalization
jamanetwork.com/journals/jamai…
The reduced risk of #LongCovid was evident in people who were
Unvaccinated
Vaccinated
Boosted
and in people with
Primary SARS-CoV-2 infection
&
Reinfection
jamanetwork.com/journals/jamai…
The risk reduction was also evident in people with
1-2 risk factors
3-4 risk factors
5 or more risk factors
jamanetwork.com/journals/jamai…
Risk reduction was evident in subgroups based on age, race, sex, and other common conditions
jamanetwork.com/journals/jamai…
How might Paxlovid reduce risk of #LongCovid ?
It is possible that hitting the virus early with an antiviral might reduce inflammation/organ damage and reduce chance of viral persistence leading to less risk of Long Covid
jamanetwork.com/journals/jamai…
What does this mean for you?
Paxlovid use in the early days after infection can reduce risk of Long Covid
The decision to use Paxlovid should consider its effectiveness in reducing risk of death & disease in both acute and post-acute phases of COVID-19
jamanetwork.com/journals/jamai…
We also learned that among people who are eligible for Paxlovid
12.67% were prescribed Paxlovid
87.33% received no antiviral treatment
This suggests the need to improve uptake of antiviral treatment
jamanetwork.com/journals/jamai…
These results apply to people who are eligible for Paxlovid under the current FDA EUA - that is people with at least 1 risk factor for progression to severe COVID-19
Whether Paxlovid reduces risk of #LongCovid in people at low risk remains to be studied
jamanetwork.com/journals/jamai…
Thanks to the amazing @sourwine for developing this press release (link below).
A clear accounting of the findings.
@WUSTLnews
@WUSTLmed
medicine.wustl.edu/news/paxlovid-…
Thank you to our reviewers, editors, and those who supported us in this project
jamanetwork.com/journals/jamai…
@WUSTL
@WUSTLmed
@WUSTLnews
@VREFSTL
@VAResearch
@vahsrd
Editorial by @DrKatzNYCHH
jamanetwork.com/journals/jamai…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.